Ophthalmology Science: Autonomous AI Diabetic Retinopathy Screening — 3-5 Year FQHC Adoption Evidence Base

A peer-reviewed Ophthalmology Science article (April 2026, also indexed PMC) reports 3-5 year real-world performance of LumineticsCore + EyeArt across health systems — including FQHCs as ideal deployment sites. Findings: nonmydriatic gradability 49–75%, sensitivity 87–100%, specificity 60–91%. Pairs with CMS CPT 92229 reimbursement of $43.67/encounter in 2025 (up from $40.94 in 2024), but adoption remains tiny (2.2% of cases since 2021, 0.09% of diabetics screened) — total addressable market is massive. Strategic implication for FQHC executives: the published peer-reviewed evidence base is now strong enough to defend AI DR screening to boards and finance committees as both a quality intervention (early DR detection prevents blindness) and a revenue line ($43.67 × diabetic panel × annual screening). Combined with the CalMatters pediatric vision exam gap and SB 776 / AB 407 implementation, FQHC vision-care expansion is a coordinated multi-modality strategic play in 2026–27.